Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | CNR2 | P34972 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7188052 | 0.92 | POLB (0.67) | TP53CNR2POLBALDH1A1MAPT | |
| SCHEMBL2930243 | 0.92 | LMNA (0.71) | TP53CNR2LMNACHRM1 | |
| SCHEMBL2938668 | 0.90 | DNTT (0.62) | TP53LMNACHRM1 | |
| SCHEMBL2936007 | 0.90 | CNR2 (0.62) | TP53CNR2LMNACHRM1 | |
| SCHEMBL2932649 | 0.89 | THRB (0.58) | TP53CNR2POLBMAPTSMN1; SMN2 | |
| SCHEMBL2937844 | 0.89 | MEN1 (0.62) | TP53CNR2LMNAPOLBCHRM1 | |
| SCHEMBL2937922 | 0.88 | LMNA (0.57) | TP53CNR2LMNACHRM1ALDH1A1 | |
| SCHEMBL2937096 | 0.86 | LMNA (0.60) | TP53CNR2LMNACHRM1 | |
| SCHEMBL2936946 | 0.86 | LMNA (0.57) | TP53LMNACHRM1ALDH1A1MAPT | |
| SCHEMBL2933160 | 0.86 | CHRM1 (0.76) | LMNAPOLBCHRM1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730135-B1 | QIUNOLIN-4-ONES AS INHIBITORS OF RETROVIRAL INTEGRASE FOR THE TREATMENT OF HIV, AIDS AND AIDS RELATED COMPLEX (ARC) | US OF AMERICA REPRESENTED BY T (US) | 2010-09-22 | — | — | EP | disclosed |
| US-7776883-B2 | Quinolin-4-ones as inhibitors of retroviral integrase for the treatment of HIV, AIDS and AIDS related complex (ARC) | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-08-17 | — | — | US | disclosed |
| US-20070219242-A1 | Quinolin-4-Ones as Inhibitors of Retroviral Integrase for the Treatment of Hiv, Aids and Aids Related Complex (Arc) | GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219242-A1 | Quinolin-4-Ones as Inhibitors of Retroviral Integrase for the Treatment of Hiv, Aids and Aids Related Complex (Arc) | QTRT1, QTRT2, CTCF | TP53 3949/4885CNR2 4590/4885LMNA 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.